Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Philip Charles Hoffman

Concepts (254)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
45
2019
938
2.040
Why?
Lung Neoplasms
52
2019
2045
1.750
Why?
Antineoplastic Combined Chemotherapy Protocols
42
2014
2223
1.400
Why?
Anemia, Hemolytic, Autoimmune
3
2009
11
0.780
Why?
Vinblastine
13
2002
108
0.680
Why?
Paclitaxel
15
2008
449
0.640
Why?
Ifosfamide
12
2003
49
0.560
Why?
Combined Modality Therapy
26
2010
1637
0.490
Why?
Esophageal Neoplasms
7
2010
348
0.450
Why?
Cisplatin
15
2010
567
0.410
Why?
Carcinoma, Squamous Cell
9
2019
1031
0.400
Why?
Antineoplastic Agents
12
2019
2335
0.380
Why?
Granulocyte Colony-Stimulating Factor
13
2008
164
0.380
Why?
Adenocarcinoma
11
2012
1213
0.360
Why?
Survival Rate
21
2019
1933
0.360
Why?
Antineoplastic Agents, Phytogenic
8
2008
298
0.350
Why?
Camptothecin
4
2008
194
0.340
Why?
Neoplasm Staging
22
2019
1900
0.340
Why?
Nucleosides
1
2006
20
0.320
Why?
Aged
51
2020
18161
0.310
Why?
Carcinoma, Small Cell
3
2004
140
0.290
Why?
Antimetabolites, Antineoplastic
2
2020
248
0.270
Why?
Middle Aged
53
2020
25178
0.270
Why?
Carboplatin
8
2008
256
0.240
Why?
Taxoids
7
2012
131
0.230
Why?
Adult
47
2020
25396
0.230
Why?
Female
57
2020
43684
0.220
Why?
Male
55
2019
41036
0.210
Why?
Salvage Therapy
2
2019
223
0.210
Why?
Dose-Response Relationship, Drug
11
2008
2082
0.210
Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2019
21
0.210
Why?
Receptor, Fibroblast Growth Factor, Type 3
1
2019
22
0.200
Why?
Antineoplastic Agents, Alkylating
3
1998
142
0.200
Why?
Humans
68
2020
80482
0.200
Why?
Remission Induction
10
2011
700
0.200
Why?
Infusions, Intravenous
5
2002
448
0.190
Why?
Benzamides
1
2019
187
0.190
Why?
Treatment Outcome
17
2014
7692
0.190
Why?
Pyrazoles
1
2019
157
0.180
Why?
Blood Group Incompatibility
2
2009
19
0.180
Why?
Piperazines
1
2019
264
0.180
Why?
Stomach Neoplasms
2
2010
271
0.170
Why?
Pneumonectomy
4
2011
182
0.170
Why?
Neoplasm Recurrence, Local
3
2012
1171
0.170
Why?
Follow-Up Studies
9
2020
3811
0.160
Why?
Aged, 80 and over
14
2020
6483
0.160
Why?
Protein Kinase Inhibitors
2
2012
561
0.150
Why?
Interferon-alpha
4
1997
239
0.150
Why?
Breast Neoplasms
3
2020
2731
0.150
Why?
Carcinoma
1
1998
431
0.150
Why?
Radiotherapy, Image-Guided
2
2012
58
0.140
Why?
Mesna
2
2008
10
0.140
Why?
Fluorouracil
9
1998
566
0.140
Why?
Exanthema
1
2014
29
0.140
Why?
Blood Proteins
1
2014
154
0.130
Why?
Leucovorin
8
1998
218
0.130
Why?
Drug Administration Schedule
12
2003
969
0.130
Why?
Ketones
1
2012
12
0.130
Why?
Organoplatinum Compounds
2
2004
99
0.130
Why?
Furans
1
2012
15
0.130
Why?
Proteomics
1
2014
187
0.120
Why?
Carcinoma, Large Cell
1
2012
40
0.120
Why?
Glutamates
2
2014
92
0.120
Why?
Prognosis
8
2020
3619
0.120
Why?
Guanine
2
2014
205
0.110
Why?
Sirolimus
1
2012
170
0.110
Why?
Thigh
1
1990
37
0.110
Why?
Recombinant Proteins
6
2008
1055
0.110
Why?
Neutropenia
6
2008
220
0.100
Why?
Cladribine
1
2009
34
0.100
Why?
Splenectomy
1
2009
92
0.100
Why?
Antibodies, Monoclonal, Murine-Derived
1
2009
80
0.100
Why?
Soft Tissue Neoplasms
1
1990
130
0.100
Why?
Lymphocyte Subsets
1
2009
69
0.100
Why?
Transplantation
1
2009
43
0.100
Why?
Immunoglobulins, Intravenous
1
2009
63
0.100
Why?
Vidarabine
1
2009
142
0.100
Why?
Lymphoproliferative Disorders
1
2009
105
0.090
Why?
Erythropoietin
1
2008
91
0.090
Why?
Drug Tolerance
3
1996
70
0.090
Why?
Survival Analysis
7
2011
1586
0.090
Why?
Disease Progression
5
2014
1441
0.090
Why?
Adrenal Cortex Hormones
1
2009
255
0.090
Why?
Venous Thromboembolism
1
2009
113
0.080
Why?
Quinazolines
1
2008
221
0.080
Why?
Thoracic Neoplasms
2
1998
59
0.080
Why?
Transplantation, Homologous
1
2009
1016
0.080
Why?
Histocompatibility
1
2006
70
0.080
Why?
Area Under Curve
2
2007
340
0.080
Why?
Drug Therapy
1
2006
77
0.080
Why?
Dacarbazine
1
2006
111
0.080
Why?
Neoplasms
3
1997
2567
0.070
Why?
Feasibility Studies
4
2008
715
0.070
Why?
Gene Amplification
2
2019
133
0.070
Why?
Radiotherapy Dosage
4
2001
465
0.070
Why?
Disease-Free Survival
4
2014
1195
0.070
Why?
Thionucleotides
1
2004
59
0.070
Why?
Cephalexin
1
2003
7
0.070
Why?
Purpura, Thrombotic Thrombocytopenic
1
2003
18
0.070
Why?
Brain Neoplasms
2
2008
786
0.070
Why?
Etoposide
4
2008
197
0.070
Why?
Survival
1
2002
23
0.070
Why?
Proto-Oncogene Proteins c-bcl-2
1
2004
193
0.060
Why?
Hematologic Neoplasms
1
2006
285
0.060
Why?
Immunosuppressive Agents
1
2009
1019
0.060
Why?
Hematopoietic Stem Cell Transplantation
1
2009
791
0.060
Why?
Maximum Tolerated Dose
4
2008
265
0.060
Why?
Time Factors
3
2014
5437
0.060
Why?
Antibodies, Monoclonal
1
2009
1489
0.060
Why?
Topoisomerase I Inhibitors
1
2001
36
0.060
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.060
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
25
0.050
Why?
Ceftizoxime
1
1999
13
0.050
Why?
Purpura, Thrombocytopenic
1
1999
7
0.050
Why?
Thrombopoietin
1
1999
12
0.050
Why?
North America
1
2000
178
0.050
Why?
Megakaryocytes
1
1999
35
0.050
Why?
Cephalosporins
1
1999
43
0.050
Why?
Europe
1
2000
310
0.050
Why?
Agranulocytosis
2
1995
23
0.050
Why?
Chemotherapy, Adjuvant
3
2015
482
0.050
Why?
Macrolides
2
2012
32
0.050
Why?
Topotecan
1
1998
45
0.050
Why?
Chemoradiotherapy
2
2011
254
0.050
Why?
Prospective Studies
2
2020
3903
0.050
Why?
Postoperative Complications
1
2009
2242
0.050
Why?
Anti-Bacterial Agents
1
2003
776
0.050
Why?
Esophagus
1
1998
122
0.040
Why?
Clinical Trials, Phase II as Topic
2
1995
169
0.040
Why?
Germ-Line Mutation
1
2020
281
0.040
Why?
Mutation
3
2015
3779
0.040
Why?
Expectorants
1
1996
5
0.040
Why?
Neoplasm Metastasis
3
2012
1037
0.040
Why?
International Agencies
1
2015
36
0.040
Why?
Chicago
3
2014
1416
0.040
Why?
Radiation-Sensitizing Agents
1
1996
106
0.040
Why?
Injections, Intravenous
1
1995
270
0.040
Why?
Genotype
1
2020
1844
0.040
Why?
Bone Marrow
4
1998
414
0.040
Why?
Cyclohexanecarboxylic Acids
1
1994
18
0.040
Why?
Hydroxyurea
4
1995
229
0.030
Why?
Esophagitis
3
1998
42
0.030
Why?
Retrospective Studies
5
2012
7284
0.030
Why?
Quality of Life
1
2020
1277
0.030
Why?
Ethers, Cyclic
1
2012
7
0.030
Why?
Lymphatic Metastasis
2
2012
505
0.030
Why?
Platinum
1
2012
51
0.030
Why?
Indoles
1
1994
327
0.030
Why?
Four-Dimensional Computed Tomography
1
2011
14
0.030
Why?
Confidence Intervals
2
2003
232
0.030
Why?
Receptors, Growth Factor
1
2011
56
0.030
Why?
Polymorphism, Single Nucleotide
1
2020
2283
0.030
Why?
Genes, ras
1
2011
99
0.030
Why?
Kaplan-Meier Estimate
1
2014
903
0.030
Why?
Neoplastic Cells, Circulating
1
2011
65
0.030
Why?
Double-Blind Method
1
2015
1857
0.030
Why?
Administration, Oral
3
2001
709
0.030
Why?
Oncogene Proteins, Fusion
1
2011
116
0.030
Why?
Whole-Body Counting
1
1989
8
0.030
Why?
Gallium Radioisotopes
1
1989
28
0.030
Why?
Proto-Oncogene Proteins c-met
1
2011
201
0.020
Why?
Hematinics
1
2008
9
0.020
Why?
Adenocarcinoma, Bronchiolo-Alveolar
1
2008
20
0.020
Why?
Cohort Studies
3
2007
2626
0.020
Why?
Predictive Value of Tests
1
2014
1682
0.020
Why?
Anemia
1
2008
125
0.020
Why?
Bone Marrow Transplantation
1
1989
292
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2014
906
0.020
Why?
Platinum Compounds
1
2007
31
0.020
Why?
Lymphoma, Non-Hodgkin
1
1990
259
0.020
Why?
Risk Factors
2
2014
5279
0.020
Why?
In Situ Hybridization, Fluorescence
1
2008
356
0.020
Why?
Drug Resistance, Neoplasm
1
2011
556
0.020
Why?
Cyclophosphamide
3
1992
286
0.020
Why?
Leukemia
1
1987
295
0.020
Why?
Drug Therapy, Combination
1
2008
978
0.020
Why?
Polyethylene Glycols
1
2008
389
0.020
Why?
Image Processing, Computer-Assisted
1
2012
1160
0.020
Why?
Neoadjuvant Therapy
1
2007
269
0.020
Why?
Radiotherapy
1
2007
341
0.020
Why?
Oligonucleotides, Antisense
1
2004
69
0.020
Why?
Bryostatins
1
2003
15
0.020
Why?
Lactones
1
2003
33
0.020
Why?
Premedication
1
2003
58
0.020
Why?
Young Adult
1
2015
5784
0.020
Why?
Sex Factors
2
2000
1082
0.020
Why?
Interleukin-6
1
2003
228
0.010
Why?
Smoking
2
2000
563
0.010
Why?
Lung
1
1987
1033
0.010
Why?
Radiation Pneumonitis
1
2001
16
0.010
Why?
Blood Cell Count
1
2001
78
0.010
Why?
Methotrexate
2
1992
256
0.010
Why?
Doxorubicin
2
1992
293
0.010
Why?
Clinical Trials as Topic
2
1998
1183
0.010
Why?
Glucocorticoids
1
2003
349
0.010
Why?
Drug Evaluation
2
1990
151
0.010
Why?
Spirometry
1
2000
65
0.010
Why?
Creatinine
1
2001
337
0.010
Why?
Forced Expiratory Volume
1
2000
112
0.010
Why?
Pilot Projects
2
1994
801
0.010
Why?
Hemolysis
1
1999
62
0.010
Why?
Platelet Count
1
1999
84
0.010
Why?
Antigen-Antibody Complex
1
1999
93
0.010
Why?
Tomography, X-Ray Computed
1
1989
2533
0.010
Why?
Tumor Necrosis Factor-alpha
1
2003
688
0.010
Why?
Isoantibodies
1
1999
117
0.010
Why?
Thorax
1
1997
51
0.010
Why?
Antibodies
1
1999
369
0.010
Why?
Isotretinoin
1
1997
21
0.010
Why?
Hematopoietic Stem Cells
1
1999
281
0.010
Why?
Antidotes
1
1997
23
0.010
Why?
Leukopenia
1
1997
65
0.010
Why?
Injections, Subcutaneous
1
1997
121
0.010
Why?
Regression Analysis
1
1998
614
0.010
Why?
Radiation Dosage
1
1997
221
0.010
Why?
Drug Synergism
1
1997
334
0.010
Why?
T-Lymphocytes
1
2003
1275
0.010
Why?
Esophagogastric Junction
1
1995
28
0.010
Why?
Incidence
1
2000
1587
0.010
Why?
Radiation Injuries
1
1996
160
0.010
Why?
Cyclohexenes
1
1994
5
0.010
Why?
Benzofurans
1
1994
8
0.010
Why?
Age Factors
1
2000
1904
0.010
Why?
Immunohistochemistry
1
1999
1806
0.010
Why?
Thrombocytopenia
1
1995
161
0.010
Why?
Palliative Care
1
1996
250
0.010
Why?
Postoperative Care
1
1995
234
0.010
Why?
Hematologic Diseases
1
1994
78
0.010
Why?
Research Design
1
1997
557
0.010
Why?
Radiotherapy, Adjuvant
1
1995
305
0.010
Why?
Procarbazine
1
1992
40
0.010
Why?
Clinical Trials, Phase I as Topic
1
1994
150
0.010
Why?
Immunologic Factors
1
1994
160
0.010
Why?
United States
1
2004
6119
0.010
Why?
Vincristine
1
1990
111
0.010
Why?
Vindesine
1
1989
9
0.010
Why?
Radiotherapy, High-Energy
1
1989
50
0.010
Why?
Bleomycin
1
1990
106
0.010
Why?
Randomized Controlled Trials as Topic
1
1994
844
0.010
Why?
Mediastinal Neoplasms
1
1989
48
0.010
Why?
Radiography, Abdominal
1
1989
65
0.010
Why?
Chi-Square Distribution
1
1990
382
0.010
Why?
Thiotepa
1
1989
31
0.010
Why?
Cytarabine
1
1990
213
0.010
Why?
Prednisone
1
1990
261
0.010
Why?
Radionuclide Imaging
1
1989
233
0.010
Why?
Melphalan
1
1989
84
0.010
Why?
Actuarial Analysis
1
1987
69
0.010
Why?
Proportional Hazards Models
1
1990
868
0.010
Why?
Karyotyping
1
1987
264
0.010
Why?
Radiography, Thoracic
1
1989
321
0.010
Why?
Multivariate Analysis
1
1990
1025
0.010
Why?
Preoperative Care
1
1989
415
0.010
Why?
Acute Disease
1
1987
851
0.000
Why?
Hoffman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_